

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Functional evaluation of Natural Killer cell cytotoxic activity in NFKB2-mutated patients

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/1655315> since 2018-01-02T12:53:57Z

Published version:

DOI:10.1016/j.imlet.2017.12.006

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



UNIVERSITÀ DEGLI STUDI DI TORINO

This is an author version of the contribution published on:

Questa è la versione dell'autore dell'opera:

Immunol Lett. 2017 Dec 24;194:40-43. doi: 10.1016/j.imlet.2017.12.006.

The definitive version is available at:

La versione definitiva è disponibile alla URL:

<http://www.sciencedirect.com/science/article/pii/S0165247817305898>

Letter to editor

Functional evaluation of Natural Killer cell cytotoxic activity in NFKB2-mutated patients

Davide Montin, MD, PhD¹, Francesco Licciardi, MD¹, Elisa Giorgio, PhD², Andrea Ciolfi, PhD³, Simone Pizzi, BSc³, Alessandro Mussa, MD, PhD¹, Raffaella Meazza, PhD⁴, Marco Tartaglia, PhD³, Alfredo Brusco, PhD², Daniela Pende, PhD⁴, and Giovanni Battista Ferrero, MD, PhD¹

¹ University of Torino, Department of Public Health and Pediatrics, Turin, 10126, Italy

² University of Torino, Department of Medical Sciences, Turin, 10126, Italy

³ Division of Genetics and Rare Diseases, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy

⁴ IRCCS AOU San Martino-IST, Immunology Laboratory, Genoa, 16132, Italy

Corresponding author:

Giovanni Battista Ferrero, MD, PhD

Department of Public Health and Pediatrics,

Piazza Polonia 64

Turin, 10126, Italy

e-mail: giovannibattista.ferrero@unito.it

Phone: +39.011.313.5219

Fax: +39.011.3135800

Declaration of all sources of funding:

Italian Ministry of Health (RC-2006) to MT; Fondazione Bambino Gesù (Vite Coraggiose) to MT; MURST 60% to AB. None of the authors has conflicts of interest to declare.

Word count: 947

Capsule Summary: defects of NK-cell cytotoxic activity have been recently reported in subjects with *NFKB2* mutations. Herein we present an extensive functional evaluation of NK cells, indicating that NK function is normal at least in some *NFKB2*-mutated patients.

Key words: immunodeficiency; NK cells; *NFKB2*

To the Editor:

Germline mutations affecting the C-terminus of NFKB2 are associated with early-onset hypogammaglobulinemia and anterior pituitary hormone deficiency. Autoimmunity and defects in peripheral T and B cells have been also described in these patients [1–4].

Recently, Lougaris et al. reported a male patient with immunodeficiency, central adrenal insufficiency, *alopecia totalis*, and trachyonychia, who carried a heterozygous truncating mutation (c.2557C>T, p.Arg853*) in *NFKB2*. The patient displayed a defective NK-cell cytotoxic activity *in vitro*, which could not be restored by the addition of human recombinant interleukin-2 (hr-IL2). Of note, NK-cell subsets showed regular expression of different NK receptors, and normal intracellular levels of perforin in terminally differentiated NK cell population. CD69 expression in mature NK cells was increased, suggesting an activated steady state [5]. Herein we report the results of an *in vitro* investigation of NK-cell function in three novel patients from two unrelated families, where we identified the same reported heterozygous mutation.

Patient 1 (II-1, family 1) is a woman born from unrelated Italian parents. At the age of six years, we diagnosed hypogammaglobulinemia with normal B cell count, following recurrent infections of upper and lower airways. At 12 years, she presented a severe hypoglycemic episode due to hypothalamic adrenocorticotrophic hormone (ACTH) deficiency, and she was treated with hydrocortisone substitution therapy. Simultaneously, we observed a severe B-cells reduction (CD19⁺ cells <1%). During follow-up, the patient presented occasional infections of the upper respiratory tract and developed *lichen planus pigmentosus* at the age of 25 years.

Patient 2 (III-1, family 1) was the second child of patient 1. Due to familial history, serum immunoglobulin and endocrinological assessment had been monitored since birth. At 12 months, immunoglobulin replacement was started, because the persistence of profound hypogammaglobulinemia, even in the absence of severe and recurrent infections. At 6

years, ACTH deficiency was diagnosed, and he was placed on treatment with hydrocortisone. He is now 8 years old, and does not present other signs or symptoms of anterior pituitary deficiency or other autoimmune features. B-cell count is still in the normal range.

Patient 3 (II-1, family 2) is a boy born from unrelated, healthy Italian parents. At 6 years, laboratory investigation was performed because of recurrent infections of upper airways and documented hypogammaglobulinemia and slightly reduced peripheral B cell population (CD19⁺ cells 3.7%). Immunoglobulin replacement treatment was started. At 10 years, he presented hypotensive shock and prolonged hypoglycemia during an episode of enteric infection. Endocrinological evaluation revealed ACTH deficiency, and substitutive therapy was started. Over the subsequent follow-up, he developed also hypothyroidism and growth hormone deficiency requiring hormone replacement therapies. B cell count is now severely reduced (CD19⁺ cells <1%).

In the context of a genetic screening program focused on immunological defects, whole exome sequencing was performed on the three patients, allowing to identify the nonsense c.2557C>T (p.Arg853*) change in *NFKB2* as the causative mutation in both families (Figure 1B). Sanger sequencing validated the identified change in probands, and genotyping confirmed co-segregation of the mutation with disease in family 1 and its *de novo* origin in family 2 (Figure 1A). The c.2557C>T (p.Arg853*) mutation had previously been reported in three unrelated cases with similar clinical features [1,6].

Extensive immunological evaluation of our three patients revealed anomalies in both T- and B-cell lineages (Table E1, Online Repository). B cells showed a slow decline over time, reaching <1% levels. We also disclosed a B-cell maturation defect, with a low switched-memory population (CD27+IgM⁻). Interestingly, follicular T helper cells were virtually absent in all patients, even before the disappearance of B cells.

Herpes viral susceptibility, reduced NK-cell levels, and defective NK-cell cytotoxic activity have been reported in *NFKB2*-mutated patients [1,2,5]. Therefore we performed an extensive functional evaluation of NK cells in order to confirm previous results and better characterize NK cells in *NFKB2*-deficient patients.

In all our patients NK cells count was normal. Surface expression of NKp46 and NKp30 (Natural Cytotoxic Receptors, NCR) - the major NK activating receptors - was similar to what observed in healthy control (Figure 2A). Intracellular expression of SLAM-Associated Protein (SAP) and perforin were also normal in NK cells (not shown).

We tested resting and activated NK-cell degranulation upon K562 stimulation, after overnight incubation of PBMC, basally or following IL2 stimulation, and measuring surface CD107a expression on CD3⁻CD56⁺ cells by cytofluorimetric analysis. In all cases, we observed normal degranulation compared with healthy control (Figure 2B).

To evaluate proliferation and expansion of polyclonal NK-cell populations, NK cells from patients and healthy controls were purified using the RosetteSep method (StemCell Technologies, Vancouver, BC, Canada), and cultured on irradiated feeder cells in the presence of phytohemagglutinin and r-IL2. The assay revealed a lower proliferation rate of *NFKB2*-mutated NK cells compared to healthy control.

To test the function of various NK cell triggering receptors, polyclonal activated NK-cell populations were tested in reverse antibody-dependent cellular cytotoxicity (R-ADCC) assays against ⁵¹Cr-labelled P815 (FcγRc⁺) murine targets, in the presence of appropriate monoclonal antibodies. All the investigated pathways demonstrated a fully activation when compared with healthy control (see Figure 2C).

In summary, we confirm c.2557C>T (p.Arg853*) is a recurrent mutation in *NFKB2*-mutated patients. We documented proper physiologic maturation and cytotoxic activity, and regular recruitment of the activation pathways in NK cells from three subjects carrying this

heterozygous mutation. A slightly reduced stimulus-dependent proliferation was the most relevant feature in these cells.

Overall, our data indicate that NK function is not significantly impaired at least in some subjects with *NFKB2* mutation, which is in contrast to what previously reported [5]. Considering the fact that our patients share the same mutation of previously reported one, it could be hypothesized that some modifying genes are needed in determining functional impairment in *NFKB2*-mutated NK cells.

Davide Montin, MD, PhD¹

Francesco Licciardi, MD¹

Elisa Giorgio, PhD²

Andrea Ciolfi, PhD³

Simone Pizzi, BSc³

Alessandro Mussa, MD, PhD¹

Raffaella Meazza, PhD⁴

Marco Tartaglia, PhD³

Alfredo Brusco, PhD²

Daniela Pende, PhD⁴

Giovanni Battista Ferrero, MD, PhD¹

From ¹University of Torino, Department of Public Health and Pediatrics, Turin, Italy; ²University of Torino, Department of Medical Sciences, Turin, Italy; ³Division of Genetics and Rare Diseases, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy; and ⁴IRCCS AOU San Martino-IST, Immunology Laboratory, Genoa, Italy.

LEGEND TO TABLE AND FIGURES

Figure 1. Families and sequence data. **A**, pedigrees of the families studied are depicted. Filled symbols indicate affected subjects; a short line above the symbol indicates available genomic DNA; “+/mut” indicates the heterozygous state for the truncating (p.Arg853*) mutation. **B**, Sanger electropherograms showing the heterozygous state for the c.2557C>T change (mut). The corresponding wild-type sequence (wt) is also reported, together with the mutated codon and nucleotide substitution.


Figure 2. NK cell phenotype and function. **A**, NK cells (CD3⁺CD56⁺ PBMC) of the three affected subjects and a healthy control (H1) were analyzed by flow-cytometry; percentage of positive cells are indicated. **B**, resting and activated NK cell degranulation assay; results are percentage of Δ CD107⁺ cells (K562 stimulated – un-stimulated). **C**, polyclonal activated NK cells were tested against ⁵¹Cr-labeled P815 target cells (E:T ratio 4:1), either in the absence (CTR) or in the presence of mAbs to the indicated molecules.

References

- [1] Chen K, Karin C, Coonrod EM, Attila K, Franks ZF, Durtschi JD, et al. Germline Mutations in NFKB2 Implicate the Noncanonical NF- κ B Pathway in the Pathogenesis of Common Variable Immunodeficiency. *Am J Hum Genet* 2013;93:812–24. doi:10.1016/j.ajhg.2013.09.009.
- [2] Liu Y, Yiwen L, Steven H, Padmalal G, Alison J, Barnaby C, et al. Novel NFKB2 Mutation in Early-Onset CVID. *J Clin Immunol* 2014;34:686–90. doi:10.1007/s10875-014-0064-x.
- [3] Lindsley AW, Yaping Q, Alexander Valencia C, Kara S, Kejian Z, Amal A. Combined Immune Deficiency in a Patient with a Novel NFKB2 Mutation. *J Clin Immunol* 2014;34:910–5. doi:10.1007/s10875-014-0095-3.
- [4] Lee CE, Fulcher DA, Whittle B, Chand R, Fewings N, Field M, et al. Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. *Blood* 2014;124:2964–72. doi:10.1182/blood-2014-06-578542.
- [5] Lougaris V, Vassilios L, Giovanna T, Massimiliano V, Manuela B, Ornella P, et al. Defective natural killer–cell cytotoxic activity in NFKB2-mutated CVID-like disease. *J Allergy Clin Immunol* 2015;135:1641–3.e3. doi:10.1016/j.jaci.2014.11.038.
- [6] Brue T, Quentien M-H, Khetchoumian K, Bensa M, Capo-Chichi J-M, Delemer B, et al. Mutations in NFKB2 and potential genetic heterogeneity in patients with DAVID syndrome, having variable endocrine and immune deficiencies. *BMC Med Genet* 2014;15:139. doi:10.1186/s12881-014-0139-9.

Figure 1

A



B






Figure 2

A



B



C

